Abstract
The increasing realization that the current vaccine for tuberculosis, bacille Calmette-Guérin (BCG), is of varying effectiveness, and is less protective in adults than in children, has prompted new research for a replacement. New research has resulted in innovative approaches, including the use of sub-unit vaccines, auxotropic vaccines, DNA vaccines, and recombinant vaccines, among others. This article reviews these approaches and test results in animal models, and discusses their potential for use in humans.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
